학술논문
Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study.
Document Type
Article
Author
Moghadasi, Abdorreza Naser; Ashtari, Fereshteh; Baghbanian, Seyed Mohammad; Shaygannejad, Vahid; Anjidani, Nassim; Ghadiri, Fereshteh; Sedighi, Behnaz; Saeidi, Morteza; Amirifard, Hamed; Ayromlou, Hormoz; Moghadam, Nahid Beladi; Ranjbar, Mohammad Bagher; Nazeri, Masoume; Niknam, Zahra; Faraji, Fardin; Afsorde, Afsaneh; Sahraian, Mohammad Ali
Source
Subject
*PREVENTION of mental depression
*MULTIPLE sclerosis
*DRUG efficacy
*RESEARCH
*DISEASE progression
*WELL-being
*CLINICAL trials
*CONFIDENCE intervals
*FUNCTIONAL status
*PSYCHOLOGICAL tests
*QUALITY of life
*DESCRIPTIVE statistics
*RESEARCH funding
*PEPTIDES
*PATIENT safety
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1029-2977
Abstract
Background: Every patient diagnosed with definite multiple sclerosis (MS) should begin disease modifying therapies. Cinnomer® contains 40 mg glatiramer acetate (GA) and is available in prefilled syringes and autoinjector devices. Methods: A phase IV multicenter study was conducted to explore the safety and effectiveness of Cinnomer® in the treatment of MS. Study-related data were collected for 14 months. Results: Totally, 368 Iranian relapsing-remitting MS patients in nine cities were enrolled. The patients were either treatment naïve (n = 191) or switchers (n = 177). Cinnomer® treatment was associated with a significant reduction in annual relapse rate (ARR) (RR: 0.65, 95% CI: 0.43, 0.98). Final mean Expanded Disability Status Scale (EDSS) scores showed improvement from baseline (difference: -0.21, 95% confidence interval (CI): -0.34, -0.08). There was a significant decrease in gad-enhancing lesions during treatment (difference: -0.38, 95% CI: -0.64, -0.12). The mean score for the depression measure (21-item BDI-II questionnaire) significantly improved (difference: -2.39, 95% CI: -3.74, -1.03). There was a significant change in the "psychological well-being" dimension (P = 0.02) (in line with BDI-II scores) and "rejection" MusiQoL dimensions (P = 0.04). The adverse events documented throughout the study were not unexpected for GA and were principally not serious. Conclusion: Safety measures were in line with the known profiles of GA. The results suggest that Cinnomer® is effective with respect to clinical outcomes and from the patient's perspective and in reducing MRI-measured MS activity. [ABSTRACT FROM AUTHOR]